Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data27
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing22
Considerations on Interim Evaluation of OS in Pivotal Oncology Trials18
A Landscape Assessment of Key Evidence Needs in Study Design and Statistical Methodologies for HTA Submissions18
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs16
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials16
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies14
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints14
Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types13
Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions12
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction11
0.085040092468262